Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My understanding is that a PR would have to be specific if new information is going to be disclosed in a private setting, even if there is a broadcast. One reason for material info to be disclosed when the market is closed is to allow investors to be prepared to react when the market opens. If material news is released when the market is open, trading is halted. There might be other technicalities that I don't know about but I think what i state is fairly accurate.
Hey Kid,
I will make a bold prediction: by the end of July AVXL stock price is going to be up, down or flat. Can we agree on that?
Keep in mind that if Dr. M. is to disclose any new material information at the conference, a PR must precede it, either today after close or tomorrow pre.
My personal opinion is that we should expect the standard corporate presentation tomorrow. The real news will be at AAIC. I would love to be wrong and we get PR tomorrow morning.
http://www.shortvolume.com/
This from NASDAQ. The other site is providing a naked short report. Not sure of the difference.
The fact is that short trading is a daily fact for all stocks and in a way a necessary evil to maintain liquidity. From my point of view, the more shorts the better the feast will be when the meal is ready.
Update is coming. The Dr. sounds very confident that things continue to move in the right direction.
The placebo effect of A-273 is so good that all patients signed up to continue trialing it for 104 additional weeks. That counts for something.
Bottom line, whether the data appears ambiguous or the trial size is too small, bla, bla, bla. There is no denying that most, if not all, of the patients in the Aussie trial experienced benefit, playing golf, painting, telling jokes, sleeping better, etc. etc., to put themselves through the hassle of extending.
If a placebo works that well, I want some....
----
NEW YORK, NY – March 10, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL) today announced that the Company has received the approval from the Ethics Committee in Australia to extend the ongoing Phase 2a Alzheimer’s trial, which had been requested by patients and their caregivers. The trial extension is designed to allow participants who complete 52 weeks in PART B to roll-over into a new trial and continue taking ANAVEX 2-73 for an additional 104 weeks, providing an opportunity to gather extended safety and efficacy data. The trial is independent of the Company’s planned larger Phase 2/3 double-blinded, placebo-controlled study of ANAVEX 2-73 in Alzheimer’s disease.
“We are receiving continued positive feedback about the effects of ANAVEX 2-73 from our study participants and their caregivers,” said Associate Professor Stephen Macfarlane, FRANZCP, Director of Aged Psychiatry at Alfred Health and the Principal Investigator of the study. “In addition to the measured cognitive and functional benefits witnessed so far, an overall improvement in mood and decrease in agitation has been anecdotally reported. We believe that extending the study will lead us to an increased understanding of the long-term effects of ANAVEX 2-73.”
For me the biggest take away from the Bloomberg interview is that it is Bloomberg. This is as mainstream as it gets in regards to financial news, and certainly more credible than CNBC. Just the fact that they invited the Dr. to speak, brief as it was, says millions about the credibility and attention that Anavex is garnering with the broader market. The story continues to build momentum.
Hang in there fellow longs, our time is nearing with every passing day, IMHO.
AAIC makes sense to deliver the "big" news if it exists. I believe it does exist.
You are right. Preclinical vs. upcoming clinical. Hopefully they will get an additional grant from MJF for the clinical.
Neiu,
I agree with you that Dr. M. continuing to deliver the message, even with no new material info, is reassuring since it is unlikely that he would be doing that if what he knows, which we don't, is not good to back up his message. He certainly sounds more convincing every time he delivers the message, even if technically is same old same old.
I may have missed it if it has been worded this way in prior announcements, but this is the first time that I caught it disclosed that the MJF foundation is fully funding the Parkinson's preclinical.
From the announcement about presenting at Jeffrey's:
"The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex a research grant to develop ANAVEX 2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX 2-73 into a Parkinson’s disease clinical trial.
Have they been awarded additional money from MJF?
Kid,
I don't often agree with your point of view but you are right to temper expectations for the Friday presentation. Unlikely that anny new material event will be announced in such a forum, unless it is made available to all via a PR when market is closed prior to the conference. That might happen but should not be expected. SEC rules.
AVXL - up 55.05% YTD.
Jan: up 13.64%
Feb: up 27.56%
Mar: no change
Apr: down 1.92%
May: Up 2.84%
Jun: up 5.96% (2 trading days).
Not too shabby. Happy camper here.
Anavex listed in the partnering section of the 2017 Bio International Convention. Companies listed in that section have access to an Ap to setup meetings with potential partners. Interesting.
BIO One-on-One Partnering™
BIO One-on-One LogoBIO One-on-One Partnering™ is the most efficient way to do business in the biotech and pharma industry without traveling all over the world. Our system makes it easy to search for and identify potential partners and request meetings with prospective biotech investors and senior business development executives.
You can invite companies and accept invitations to meet, and once your meetings are mutually accepted, BIO does the scheduling so you arrive to BIO with a plan! Partnering is now open.
LOGIN TO PARTNERING
Power,
Just as you posted I was about to do the same. The only place I could find Anavex was under partnering, as you mentioned. Partnering? Very interesting.
https://mybio.org/exhibitor/exhibitor?exhibitor_page=11&filter_by_tags=46133&tag_ids=46133
Hear! Hear!
We believe!
sell'em if you got'em.
Wrong again!
...one more thing. This is why we believe:
In December 2014, a Phase 2a clinical trial was initiated for ANAVEX 2-73TM, which is being evaluated for the treatment of Alzheimer’s disease. The open-label randomized trial is designed to assess the safety and exploratory efficacy of ANAVEXTM 2-73 in 32 patients with mild to moderate Alzheimer’s disease. ANAVEXTM 2-73 targets sigma-1 and muscarinic receptors, which have been shown in preclinical studies to reduce stress levels in the brain believed to restore cellular homeostasis and to reverse the pathological hallmarks observed in Alzheimer’s disease. ANAVEXTM 2-73 showed no serious adverse events in a previously performed Phase 1 study. In pre-clinical studies ANAVEXTM 2-73 demonstrated anti-amnesic and neuroprotective properties in various animal models including the transgenic mouse model Tg2576.
The Phase 2a study met both primary and secondary objectives of the study. The 31-week preliminary exploratory safety and efficacy data from the ongoing Phase 2a study of ANAVEXTM 2-73 in Alzheimer’s patients, with most also receiving donepezil, the current standard of care, demonstrated favorable safety, maximum tolerated dose, positive dose response, sustained efficacy response through 31 weeks for both cognitive and functional measures, as well as positive unexpected therapeutic response events. ANAVEXTM 2-73 continues to demonstrate a favorable adverse event profile through 31 weeks in a patient population of elderly Alzheimer’s patients with varying degrees of physical fragility. The most common side effects across all adverse events categories tended to be of mild severity grade 1, and were resolved with dose reductions that were anticipated within the adaptive design of the study protocol.
At 41 weeks, Alzheimer’s patients taking a daily oral dose of ANAVEXTM 2-73 in the exploratory, not yet dose optimized Phase 2a clinical trial, showed a stabilization of cognitive and functional measures. This data of stabilization is promising since Alzheimer’s disease is a progressive disease where current therapeutics are only able to temporarily slow the worsening of dementia symptoms and do not stop the disease from progressing. At 41 weeks, oral daily dosing between 10mg and 50mg, ANAVEXTM 2-73 was well tolerated, and no patients discontinued treatment due to adverse events. There were no clinically significant treatment-related adverse events, and no serious adverse events.
Pre-specified exploratory analyses included the cognitive (MMSE) and the functional (ADCS-ADL) changes from baseline. A continued stabilization of both cognitive (MMSE) and functional (ADCS-ADL) measures in patients treated with ANAVEXTM 2-73 was observed. This correlation was positive with all measured scores (MMSE, ADCS-ADL, Cogstate, HAM-D and EEG/ERP).
ANAVEXTM 2-73 data presented meets prerequisite information in order to progress into Phase 2/3 placebo controlled studies, which are currently in the planning phase.
Recent preclinical data validates ANAVEXTM 2-73 as a prospective platform drug for other neurodegenerative diseases beyond Alzheimer’s as well as neurodevelopmental diseases, more specifically, Parkinson’s disease, epilepsy and Rett syndrome. For Parkinson’s disease, data demonstrates significant improvements and restoration of function in a classic animal model of Parkinson’s disease. Significant improvements were seen on all measures tested: behavioral, histopathological, and neuroinflammatory endpoints. For epilepsy, data demonstrates both significant and dose related improvement in the reduction of seizures, as well as significant synergy with each of three generations of epilepsy drugs currently on the market. In Rett syndrome, a rare neurodevelopmental disease indication, administration of ANAVEXTM 2-73 resulted in both significant and dose related improvements in an array of behavioral paradigms in the MECP2 HET Rett syndrome disease model.
Recent preclinical data presented also indicates that ANAVEXTM 2-73 demonstrates protective effects of the mitochondrial enzyme complexes I and IV during pathological conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases. The U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to ANAVEXTM 2-73 for the treatment of Rett syndrome and infantile spasms, in May 2016 and June 2016, respectively.
You had to mention AFartstain. Ruined my day-:)
Mc,
Did you mention that A2-73 works?
This should tell you how credible the writer is:
----
honeymoonerz
Comments (3) |+ Follow |Send Message
Amit, you reference Toyama in your article as having the a similar compound as A2-73 and they reference Patent- Alkyl ether derivatives or salts thereof US RE43676 E1
After reading through the only Patent Toyama has with regards to Alzheimers, the two seem different to me.
T-817MA (1-{3-[2-(1-benzothiop... ethoxy] propyl}-3-azetidinol maleate)
A2-73- 1-[4-[(1-Adamantyl)phe... chloridrate, 1-[4-[(1-Adamantyl)phe... bichloridrate, 1-[a-(1-Adamantyl)diph... bichloridrate
Can you share with us your research that indicates these are similar?
19 May 2017, 03:09 PM Report Abuse Reply 0 Like
Amit Ghate, Contributor
Comments (339) |+ Follow |Send Message
Author’s reply » I said a similar mechanism of action not a similar compound. And then the basis is the AF quote I supplied.
-----
Attila,
10-q is filed quarterly. It is typically filed a month or so into the next quarter. For that reason, even if something it is already public when the 10-q is filed, it would not make it into the current one if that event occurs in the current quarter.
I understand the frustration about the lack of meaningful announcements, which we all have been waiting for anxiously. I happen to remain a believer in the science, the CEO and the BOD. Hopefully patience will be rewarded. That said, there are no guarantees, especially in the highly speculative biotech sector.
Good luck!
Up my game? Management gets awarded stock for all kinds of reasons. In this case it could have been for a past event, or a milestone that will lead to a material event which will need to be disclosed when it happens.
Most of what is written on this board is speculation. Your comment, even with the condescending bent, is just that.
Good luck, whatever your game is.
Looks like the AH trade for 50 shares at 6.20 held. Tomorrow's pre-market should give us an indication of it's meaning. Hopefully good news.
The options he got in this round are worth nothing right now since they have a strike price of 5.92. His incentive is to grow PPS to cash in.
We may know more about reason for award with next 10-q. Perhaps, hopefully, we will know before with announcement about trials and/or partnership.
MM's sometimes execute a trade to set the new floor for next day's trading.
Happy to be a member of this cult. Sorry for those who join basher cults.
Only 50 shares so don't get to excited. Let's see where we are when after hours session ends. Hopefully some good news coming.
The CEO does not give himself shares. The BOD decides what he gets. Obviously, he most have achieved a certain milestone which resulted in him and the CFO receiving options. These options are worth something ig the PPS goes up from current levels.
To all who complain so much about the CEO compensation, lack of PR's, low PPS, etc., etc., you have an option, sell your shares. Plenty of institutions are waiting for you to pass them on to their pile.
Whining on this or any other message board is not going to change a thing. The CEO is following a plan and things will happen when they happen. News will be available when there is something to "news" about. You either believe or you don't.
Top 5 Holders of Institutional Holdings
1. BLACKROCK INC. 1,605,252
2. PARK WEST ASSET MANAGEMENT LLC 1,500,000
3. VANGUARD GROUP INC 1,485,681
4. BLACKROCK FUND ADVISORS 1,057,856
5. KNOLL CAPITAL MANAGEMENT, LP 724,205
Read more: http://www.nasdaq.com/symbol/avxl/ownership-summary#ixzz4gzmLRFXD
My guess is anywhere between 25 and 28%
I don't believe the 21.10% includes all fillings for the quarter. Nevertheless, Anavex continues to be acquired by institutions which bods well for SP, obviously coupled with positive results/news.
-----------------------------
Anavex Life Sciences Corp. (:AVXL) is Catching the Eye of Institutions
May 11, 2017 Benjamin Lawrence
According to the SEC’s latest filings, institutions owning shares of Anavex Life Sciences Corp. (:AVXL) have increased their transactions by 8.98%. Institutions now own 21.10% of the company.
Organizations that control large sums of money, like pension funds, insurance companies or mutual funds, who buy stocks are known as institutional investors. Compared to individual investors, institutional investors trade in large blocks, 10,000 or more shares per transaction. These large trades can affect the price of a commodity significantly.
Investors look favorably upon stocks with a large amount of institutional ownership. These large entities often hire a team of analysts to perform research prior to the group purchasing a company’s stock. Because of the large research investment made, institutions aren’t quick to sell their position.
Institutions may also influence the price of a stock after acquiring a position by using TV shows, articles in high-profile newspapers or magazines and presentations at investor conferences to help drive the price higher, increasing the value of the share.
TECHNICAL INDICATORS
Anavex Life Sciences Corp. (:AVXL) stock stands 2.89% away from its 50-day simple moving average and also 38.70% away from the 200-day average. Recently, the commodity stands -28.07% away from the 52-week high and 145.68% from the 52-week low. The RSI (Relative Strength Index), an indicator that shows price strength by comparing upward and downward close-to-close movements is 55.00 for Anavex Life Sciences Corp. (:AVXL).
https://midwaymonitor.com/anavex-life-sciences-corp-avxl-is-catching-the-eye-of-institutions/87031/
Sent the following to IR this Morning. They know me as I write to them from time to time. Typically they respond the next day.
------
Hello,
Pleased to see the hiring of Dr. Fadiran. Is Christina Capiac still with the company? If so, why was there no mention of her and the role she will have now?
Looking forward to your prompt response.
Thank you
XXXXXXXXXXX
Investor
----------------
I hope so as well. Keep in mind that the Rett Foundation has a lot of say on the trial composition since they are sourcing the patients and providing funding.